The strategic acquisition of Mirati will enhance BMS’ oncology portfolio with new cancer treatments. Credit: nitpicker/Shutterstock.com.

BMS has concluded the acquisition of Mirati Therapeutics for $5.8bn, a move that significantly bolsters and diversifies its oncology portfolio.

The acquisition was initially agreed upon in October 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A commercial-stage targeted oncology company, Mirati is known for its focus on discovering, designing and developing cancer treatments.

On the deal’s closure, Mirati ceased trading on the NASDAQ Global Select Market and became a wholly owned BMS subsidiary.

The acquisition brings KRAZATI (adagrasib), a lung cancer medicine, into BMS’ oncology portfolio.

The company has also gained access to clinical assets including a Phase I MTA-co-operative PRMT5 inhibitor and a KRAS programme with two candidates in the Phase I stage of development.

These additions bolster BMS’ position in targeted oncology.

The deal is anticipated to be dilutive to BMS’ non-GAAP [generally accepted accounting principles] earnings per share by $0.35 in 2024.

The transaction will be treated as a business combination.

Evercore and Morgan Stanley advised BMS on financial aspects of the acquisition and Kirkland & Ellis LLP provided legal counsel.

Mirati received financial advice from Centerview Partners and legal guidance from Skadden, Arps, Slate, Meagher & Flom.

Bristol Myers Squibb CEO Chris Boerner stated: “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond.

“Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary to BMS.

“We welcome them and look forward to working together to leverage BMS’ global scale and resources to deliver more treatments for cancer patients, faster.”